Pembrolizumab After Completion of Locally Ablative Therapy for Oligometastatic Non–Small Cell Lung Cancer: A Phase 2 Trial

IMPORTANCE: Patients with oligometastatic non–small cell lung cancer (NSCLC) may benefit from locally ablative therapy (LAT) such as surgery or stereotactic radiotherapy. Prior studies were conducted before the advent of immunotherapy, and a strong biological rationale for the use of immunotherapy e...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:JAMA Oncol
Main Authors: Bauml, Joshua M., Mick, Rosemarie, Ciunci, Christine, Aggarwal, Charu, Davis, Christiana, Evans, Tracey, Deshpande, Charuhas, Miller, Linda, Patel, Pooja, Alley, Evan, Knepley, Christina, Mutale, Faith, Cohen, Roger B., Langer, Corey J.
Formato: Artigo
Idioma:Inglês
Publicado em: American Medical Association 2019
Assuntos:
Original Investigation
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6624820/
https://ncbi.nlm.nih.gov/pubmed/31294762
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1001/jamaoncol.2019.1449
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados